IgG4/IgG RNA ratio does not accurately discriminate IgG4-related disease from pancreatobiliary cancer

Authors
Elsemieke de Vries, Floor Tielbeke, Lowiek Hubers, Jeltje Helder, Nahid Mostafavi, Joanne Verheij, Jeanin van Hooft, Marc Besselink, Paul Fockens, Niek de Vries, Ulrich Beuers

Correspondence
u.h.beuers@amsterdamumc.nl (U. Beuers).

Highlights

- IgG4-related disease and malignancy of bile ducts/pancreas can be indistinguishable.

- Blood IgG4/IgG RNA ratio was prospectively tested as an IgG4-RD marker when malignancy was suspected.

- IgG4/IgG RNA ratio >5% did not accurately discriminate IgG4-RD from pancreatobiliary cancer.

Lay summary

IgG4-related disease is a benign inflammatory multi-organ disease which predominantly affects the pancreas and biliary tree. Clinical symptoms, laboratory and imaging finding are often difficult to distinguish from pancreatic or biliary tract cancer. This prospective trial indicates that the recently proposed blood IgG4/IgG RNA ratio does not accurately distinguish benign IgG4-RD from malignant pancreatobiliary disease.

https://doi.org/10.1016/j.jhepr.2020.100116
IgG4/IgG RNA ratio does not accurately discriminate IgG4-related disease from pancreatobiliary cancer

Elsemiek de Vries,1,3 Floor Tielbeke,1,7 Lowiek Hubers,1 Jeltje Helder,1 Nahid Mostafavi,1 Joanne Verheij,2 Jeanin van Hooft,1 Marc Besselink,3 Paul Fockens,1 Nieke de Vries,4 Ulrich Beuers1,†

1 Department of Gastroenterology & Hepatology, The Amsterdam Gastroenterology & Metabolism (AG&M) Research Institute; 3 Department of Pathology, The Amsterdam Gastroenterology & Metabolism (AG&M) Research Institute; 1 Department of Surgery, Cancer Center Amsterdam; 2 Department of Rheumatology & Clinical Immunology, all at Amsterdam UMC, University of Amsterdam, The Netherlands

JHEP Reports 2020. https://doi.org/10.1016/j.jhepr.2020.100116

Background & Aims: IgG4-related disease (IgG4-RD) of the biliary tract and pancreas is often difficult to distinguish from pancreatobiliary cancer. The blood IgG4/IgG RNA ratio has been reported to discriminate IgG4-RD from primary sclerosing cholangitis/pancreatobiliary cancer with high accuracy. This study aimed to prospectively assess the diagnostic accuracy of the blood IgG4/IgG RNA ratio for distinguishing IgG4-RD from cancer in patients with a suspected pancreatobiliary malignancy.

Methods: In this prospective, single center, observational study, patients presenting at a specialized multidisciplinary, hepatopancreato-biliary clinic with suspicion of pancreatobiliary malignancy were included. The IgG4/IgG RNA ratio (threshold 5.0%) was determined by quantitative PCR in addition to standard diagnostic procedures. Clinical, biochemical, radiological, and histo-/cytopathological findings were analyzed. For the diagnosis of IgG4-RD, the HISORt criteria were used as a reference standard. Malignancy was defined by the presence of neoplastic tissue at histo-/cytopathological examination.

Results: Overall, 213 consecutive patients (mean age 68 years) with a suspected pancreatobiliary malignancy were analyzed, of whom 3 patients were diagnosed with IgG4-RD and 178 patients were diagnosed with malignancy (165 patients with primary pancreatobiliary malignancy). The IgG4/IgG RNA ratio was true positive in 3 patients and false positive in 87 (40.8%) patients. In 123 (57.7%) patients the test was true negative. The sensitivity of blood IgG4/IgG RNA ratio was 100%, the specificity 58.6%, the positive predictive value 3.3%.

Conclusion: In the setting of a high a priori risk of malignancy, an elevated IgG4/IgG RNA ratio did not accurately discriminate pancreatobiliary cancer from IgG4-RD as illustrated by low specificity and concordant low positive predictive value. We advise against the use of this test to discriminate IgG4-RD from pancreatobiliary malignancies.

© 2020 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Keywords: Cholangiocarcinoma; IgG4-related cholangitis; Klatskin tumor; pancreatic carcinoma; pancreatobiliary malignancy.

Received 12 January 2020; received in revised form 1 April 2020; accepted 1 April 2020; available online 14 April 2020

Introduction

Immunogloblin G4-related disease (IgG4-RD) is a systemic immune-mediated disease which affects various organs, predominantly the pancreas, bile ducts and salivary glands.1 IgG4-RD of the pancreas (auto-immune pancreatitis [AIP] type 1) and the bile ducts (IgG4-related cholangitis, IRC) are benign inflammatory diseases which are responsive to corticosteroid treatment.2,3 Diagnostic criteria such as the HISORt criteria including histopathological (H), imaging (I), serological (S) features, other organ manifestations of IgG4-RD (O) and response to treatment (Rt), have been developed to diagnose pancreatobiliary IgG4-RD.3 Still, the accuracy of these diagnostic criteria is limited and AIP type I and IRC remain difficult to distinguish from pancreatobiliary malignancies or primary/secondary sclerosing cholangitis.4,5 Clinical signs and symptoms of obstructive jaundice, weight loss and abdominal discomfort are frequently seen in AIP and IRC as well as in pancreatobiliary malignancies. On imaging, pancreatic mass and biliary strictures or mass-forming lesions are seen in both conditions as well.6 Unfortunately, misdiagnosis is common and may result in unnecessary surgical interventions or systemic chemotherapy in patients with IgG4-RD. The rate of unexpected benign disease after hemihepatectomy for presumed cholangiocarcinoma or pancreatoduodenectomy for presumed pancreatic ductal carcinoma still ranges from 5 to 15%,6–8 with IgG4-RD being a major contributor.8 Remarkably, up to a third of patients with IgG4-RD may undergo major surgery due to presumed malignancy prior to an accurate diagnosis of IgG4-RD.10 IgG4 serum levels have limited diagnostic value when only modestly elevated (<4x the upper limit of normal), since 10–15% of patients with pancreatobiliary cancers and primary sclerosing cholangitis (PSC) may also exhibit increased IgG4 serum levels.10–12 Moreover, up to 30% of patients with IgG4-related pancreatobiliary disease
have normal serum IgG4 levels.\textsuperscript{3,13} Histo- or cytopathological confirmation of malignancy is often difficult to obtain, particularly of a hilar mass, and histological differentiation between benign and malignant pancreatobiliary entities can be challenging. Elevated carbohydrate antigen (CA) 19.9 level is not sufficient to differentiate between benign and malignant pancreatobiliary disease with obstructive jaundice.\textsuperscript{14}

Our group recently proposed blood IgG4/IgG RNA ratio, determined by quantitative PCR (qPCR), as a diagnostic test to discriminate IgG4-RD from PSC or pancreatic cancer\textsuperscript{12} based on the high accuracy (94% sensitivity; 99% specificity) of this test for distinguishing patients with IgG4-RD from those with PSC and biliary/pancreatic cancer.\textsuperscript{15} The present study aimed to detect IgG4-RD in patients presented consecutively with suspected biliary or pancreatic cancer, in order to prevent misdiagnosis by determining the blood IgG4/IgG RNA ratio by qPCR for the diagnosis of IgG4-RD.

### Patients and methods

In this prospective, observational, single center study, all consecutive patients of ≥18 years of age presenting at a specialized multidisciplinary hepatopancreato-biliary clinic, at the Amsterdam UMC, with suspected or proven biliary or pancreatic cancer were included between February 21\textsuperscript{st} and September 4\textsuperscript{th}, 2019. Standard diagnostic procedures were performed including laboratory assessment (hemoglobin, mean corpuscular volume, leukocytes, erythrocytes, platelets, creatinine, albumin, blood urea nitrogen, glucose, potassium, sodium, total bilirubin, alkaline phosphatase, gamma-glutamyltransferase, alanine aminotransferase, aspartate aminotransferase, prothrombin time, CA19.9, IgG and IgG4), radiographic imaging (ultrasound, CT and/or MRI) and histo-/cytopathological analysis. In addition, the blood IgG4/IgG RNA ratio was determined and considered positive if the ratio was >5.0%.\textsuperscript{12}

The exact method for determining the IgG4/IgG RNA ratio has been extensively described.\textsuperscript{12} In brief, RNA was isolated from peripheral blood and processed. Complementary DNA (cDNA) was synthesized from RNA using Superscript III RT (Invitrogen Life Technologies, Carlsbad, CA). IgG and IgG4 primers for qPCR were designed to specifically amplify sequences that encode the constant region of the heavy chain of the receptor. Additionally, the following rules were applied: (1) 2 different reverse primers were designed, one for all possible IgG subtypes and one specific for the IgG4 subtype, and (2) the 2 reverse primers were designed on virtually the same position to allow comparable conditions. After optimization, this resulted in 1 universal forward primer (5’-CGTCCCTGCTCAAGGACTAC-3’), 1 generic IgG reverse primer (5’-CTCTTCCACCTGTGTTG-3’), and 1 specific IgG4 reverse primer (5’-CTACGTTGCAGGTGTAGGTCTTC-3’). Duplicate qPCR reactions were performed in a 10 µl total volume in the presence of 10 pmol of the forward and reverse primers, cDNA from 50 ng RNA input, and 5 µl of SensiFAST SYBR Lo-ROX reagent (catalog no. BIO-94005, Bioline; GC Biotech, Alphen aan den Rijn, Netherlands) for 40 cycles (95°C for 2 minutes, 40 cycles [95°C for 5 seconds, 60°C for 10 seconds, and 72°C for 20 seconds], followed by a melting curve [95°C for 5 seconds, 65°C for 1 minute, and 97°C continuous]), using the LightCycler 480 system (Roche Diagnostics, Almere, The Netherlands). Both for IgG and IgG4, the starting concentrations in the sample were calculated using LinRegPCR software\textsuperscript{15} and used to calculate the percentage of IgG+ RNA molecules that were IgG4+.\textsuperscript{12}

Clinical, laboratory, imaging and histo-/cytopathological findings were prospectively collected from all patients investigated and treated. Patients were discussed in a weekly multidisciplinary meeting in the presence of at least 1 surgeon, gastroenterologist, oncologist, pathologist and radiologist. Histo-/cytopathological findings were analyzed in patients who underwent a biopsy, brush or surgical intervention of the biliary tract or pancreas. For the diagnosis of IgG4-RD, the HISORt criteria were used as a reference standard.\textsuperscript{15} Malignancy was defined by the presence of neoplastic tissue/cells at histo-/cytopathological examination. Patients with high suspicion of IgG4-RD and no proven malignancy, were treated with prednisolone (30–40 mg daily) for 2–4 weeks and were then reevaluated by laboratory tests and imaging to monitor tumor response.

### Sample size calculation

Every year approximately 450–500 patients are seen at the specialized outpatient hepatopancreato-biliary clinic. Based on the assumption that every year circa 5 new patients with IgG4-RD will present, 1,000 patients had to be screened in 2 years to identify 10 patients with IgG4-RD. In order to evaluate the predictive value of the clinical decision model to distinguish between IgG4-RD of the biliary tract or pancreas and cancer, a minimum of 10 patients with IgG4-RD had to be tested, to allow for 1 false negative result, based on a sensitivity of 94% and a specificity of 99% of the IgG4/IgG RNA ratio. Using the IgG4/IgG RNA ratio alone, we estimated to have 1 false negative and 10 false positive results. However, when combining the accuracy of blood IgG4/IgG RNA ratio for IgG4-RD with brush cytology for cholangiocarcinoma and pancreatic carcinomas (sensitivity 30–50%, specificity 99%), EUS-FNA for pancreatic carcinoma (sensitivity 80%, specificity 100%) and biopsies of presumed metastases, we aimed to lower the number of false positive test results from 10 to 3. On the other hand, 9 patients would be diagnosed correctly with IgG4-RD and would be saved from unnecessary surgery or chemotherapy.

An interim analysis of this open, prospective, single center trial was performed in September 2019 and the study was subsequently stopped on September 10, 2019.

### Statistical analysis

The predictive value of the blood IgG4/IgG RNA ratio was calculated with a true positive test defined as an elevated IgG4/IgG RNA ratio ≥5% in combination with response to prednisolone treatment. A false positive test was defined as an elevated IgG4/IgG RNA ratio ≥5% in combination with a histopathologically proven malignancy or clear evidence of a benign disease different from IgG4-RD. A false negative test was defined as an IgG4/IgG RNA ratio <5% and benign histo-/cytopathology with histological features of IgG4-RD (tissue infiltration of >10 IgG4+ plasma cells per high power field (HPF) in biopsy or >50 IgG4+ plasma cells per HPF in organ resection material, in combination with lymphoplasmacytic infiltration, storiform fibrosis and/or obliterator phlebitis\textsuperscript{16}) after biopsy/resection for a presumed malignancy. The test was considered true negative if histo-/cytopathology showed signs of malignancy or clear evidence of a benign disease different from IgG4-RD in combination with an IgG4/IgG RNA ratio ≤5%. Statistical differences between benign and malignant disease for serum levels of IgG4, CA 19.9 and
blood IgG4/IgG RNA ratio were evaluated using Wilcoxon-Mann-Whitney test. All statistical testing was 2-sided and performed at the 0.05 significance level ($p < 0.05$) using SPSS version 25 (IBM SPSS statistics).

The study protocol was approved by the Medical Research and Ethics Committee of the Amsterdam UMC, location AMC (W18_263 # 18.328).

**Results**

A total of 213 consecutive patients presenting at a specialized multidisciplinary hepatopancreatobiliary outpatient clinic for suspicion of hepatobiliary malignancy were investigated between February and September, 2019. One hundred and four patients (48.8%) were male and 109 (51.2%) were female, with a mean ($\pm$SD) age of 68 $\pm$ 11 years. Demographic, clinical and biochemical characteristics are summarized in Table 1. A benign disease was diagnosed in 35 patients (16.4%): 7 patients were diagnosed with cholecystitis and/or cholecysto-/cholangiokololithiasis, 7 patients with chronic pancreatitis or AIP type 2, 10 patients with a pancreas cyst, and 8 patients with other benign diseases or no abnormalities. In this cohort no patients were diagnosed with PSC. Based on clinical, laboratory and imaging findings, 3 patients (1.4%) were diagnosed with IgG4-RD. All 3 patients were male with a mean age of 74 years, the blood IgG4/IgG RNA ratio was elevated (resp. 10.9%, 37.9% and 41.2%) and in 2 of the 3 patients serum IgG4 was more than 10× elevated (>14.0 g/L).

**Table 1. Clinical and biochemical characteristics of 213 consecutive patients presenting with suspected or proven hepatopancreatobiliary malignancies.**

| Characteristics                  | Age, years [mean ± SD] | Sex, male/female | Total bilirubin, $\mu$mol/L | Alkaline phosphatase, U/L | Gamma-glutamyltransferase, U/L | Aspartate aminotransferase, U/L | Alanine aminotransferase, U/L | IgG4/IgG RNA, % | IgG4, g/L | Carbohydrate antigen 19.9, kU/L |
|----------------------------------|------------------------|------------------|-----------------------------|---------------------------|--------------------------------|--------------------------------|-------------------------------|----------------|-----------|-------------------------------|
| **IgG4-RD**                      | 68 ± 11                | 104 (49%) / 109 (51%) | 15 (8–95)                   | 175 (85–395)              | 124 (35–911)                   | 37 (22–85)                    | 51 (22–117)                  | 3.9 (2.0–8.0)  | 0.48 (0.25–0.88) | 127 (19–1235)               |
| **Non-IgG4 Malignancy/other benign disease** | 210                    |                  |                             |                           |                                |                                |                               |                |           |                               |
| **IgG4-RD**                      | 213                    |                  |                             |                           |                                |                                |                               |                |           |                               |
| **IgG4-RD**                      | True positive          | False negative   | False positive              | True negative             |                                |                                |                               |                |           |                               |
| **IgG4-RD**                      | Population             | 3                 | 0                           | 87                        | 123                            |                                |                               |                |           |                               |

Results of laboratory tests are presented as medians (IQR).

**Table 2. Comparison of characteristics of patients tested true negative and false positive using IgG4/IgG RNA ratio in blood.**

| Patient characteristics | True negative n = 123 | False positive n = 87 | p value* |
|-------------------------|-----------------------|------------------------|----------|
| Gender, n (%)           |                       |                        | 0.51     |
| Female                  | 61 (49.6%)            | 48 (55.2%)             |          |
| Male                    | 62 (50.4%)            | 39 (44.8%)             |          |
| Diagnosis, n (%)        |                       |                        | 0.08     |
| Pancreatic carcinoma    | 61 (49.6%)            | 49 (56.3%)             |          |
| Cholangiocarcinoma      | 26 (21.1%)            | 11 (12.6%)             |          |
| Gallbladder carcinoma   | 6 (4.9%)              | 1 (1.1%)               |          |
| Papil carcinoma         | 4 (3.3%)              | 7 (8.0%)               |          |
| Primary malignancy unknown | 0 (0%)             | 2 (2.3%)               |          |
| Other malignancy        | 5 (4.1%)              | 6 (6.9%)               |          |
| Benign disease          | 21 (17.1%)            | 11 (12.6%)             |          |
| Symptoms, n (%)         |                       |                        |          |
| Jaundice                | 47 (38.2%)            | 28 (32.2%)             | 0.45     |
| Abdominal discomfort    | 80 (65.0%)            | 48 (55.2%)             | 0.19     |
| Pruritus                | 23 (18.7%)            | 26 (29.0%)             | 0.09     |
| Fever                   | 3 (2.4%)              | 0 (0%)                 | 0.38     |
| Decreased appetite      | 39 (31.7%)            | 24 (27.6%)             | 0.63     |
| Weight loss             | 67 (54.5%)            | 51 (58.6%)             | 0.48     |
| Age, mean (SD)          | 67.4 (11.8)           | 67.7 (11.0)            | 0.85     |
| Biochemical tests, mean (SD) |                |                        |          |
| C-reactive protein      | 19.9 (29.0)           | 17.7 (29.2)            | 0.59     |
| Bilirubin               | 88.3 (142)            | 95.1 (146)             | 0.74     |
| Alkaline phosphatase    | 306 (318)             | 297 (321)              | 0.85     |
| Gamma-glutamyltransferase | 364 (511)          | 353 (541)              | 0.88     |
| Aspartate aminotransferase | 68 (74)              | 71 (77)                | 0.78     |
| Alanine aminotransferase | 103 (150)            | 112 (160)              | 0.67     |
| Carbohydrate antigen 19.9 | 2,110 (8,160)       | 2,200 (7,170)          | 0.94     |
| IgG4                    | 0.59 (0.55)           | 0.69 (0.58)            | 0.25     |

Categorical variables are presented as n (%). Continuous variables are presented as mean (SD).

*Continuous variables have been tested using Student’s t test, categorical variables have been tested using Chi-square test.
Abstract

In patients presenting at a dedicated outpatient clinic with suspected or proven biliary or pancreatic cancer, the accuracy of an elevated IgG4/IgG RNA ratio to discriminate pancreatic and biliary cancer from IgG4-RD was poor, as demonstrated in this open prospective DIPAC trial. The results of the interim analysis led us to stop the trial and advise against the use of this test for discrimination of IgG4-RD from biliary and pancreatic malignancies outside a research setting. Retrospective re-analysis of a large cohort of hepato-pancreato-biliary patients is underway to understand the discrepancy between previous and actual results regarding a diagnostic value of the blood IgG4/IgG RNA ratio.

Keywords

IgG4-RD, IgG4, RNA ratio, pancreatic cancer, bile duct dilatation, bile duct cancer, benign disease, malignant disease, malignancies, ductal carcinoma, biliary cancer, biliary obstruction, CA19.9, IgG4/IgG RNA ratio, AUC, diagnosis, discrimination, pancreatic cancer, biliary cancer, benign disease, diagnostic test, retrospective analysis, prospective trial, interim analysis.

Introduction

IgG4-related disease (IgG4-RD) is a clinicopathological syndrome that affects multiple organs and is characterized by a prominent infiltration of IgG4-positive plasma cells and lymphocytes. It is a major etiological factor for chronic, indolent periampullary biliary obstruction and may mimic neoplasms such as benign or malignant biliary or pancreatic tumors. The diagnostic criteria have been described in detail elsewhere. 

The blood IgG4/IgG ratio was true positive in 3 patients with IgG4-RD (3.3%) and false positive (median IgG4/IgG RNA ratio 9.8%, IQR 6.3–15.2) in 87 patients (40.8%) with other benign or malignant disease. In 123 patients (58.6%) the test was true negative (Fig. 1). Receiver operating characteristics (ROC) curve analysis revealed an area under the curve (AUC) for IgG4/IgG RNA ratio of 0.793 to predict IgG4-related disease (sensitivity 100%, specificity 58.6%). No differences were observed in patient characteristics (age, gender, symptoms at presentation, biochemical tests, diagnosis) between patients with a false positive test (n = 87) in comparison to patients with a true negative test (n = 123) (Table 2).

CA19.9 differentiated benign and malignant diseases (p <0.01), but no difference in serum IgG4 or blood IgG4/IgG RNA ratio (p = 0.6, each) between these groups was observed (Table 3). An AUC for CA19.9 of 0.721 to predict malignant disease in this cohort (sensitivity 73.6%, specificity 70.6%) was reached.

Discussion

In patients presenting at a dedicated outpatient clinic with suspected or proven biliary or pancreatic cancer, the accuracy of an elevated IgG4/IgG RNA ratio to discriminate pancreatic and biliary cancer from IgG4-RD was poor, as demonstrated in this open prospective DIPAC trial. The results of the interim analysis led us to stop the trial and advise against the use of this test for discrimination of IgG4-RD from biliary and pancreatic malignancies outside a research setting. Retrospective re-analysis of a large cohort of hepato-pancreato-biliary patients is underway to understand the discrepancy between previous and actual results regarding a diagnostic value of the blood IgG4/IgG RNA ratio.

Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhepr.2020.100116.

Table 3. Discriminant function of laboratory tests for benign vs. malignant hepatopancreaticobiliary disease in 213 consecutive patients presented at a specialized multidisciplinary outpatient clinic.

| Test                               | Benign disease (n = 35) | Malignant disease (n = 178) | p value |
|------------------------------------|-------------------------|-----------------------------|---------|
| IgG4/IgG RNA ratio, %              | 4.0 (2.1–6.9)           | 3.9 (2.0–8.2)               | 0.6     |
| IgG4, g/L                          | 0.4 (0.3–1.1)           | 0.5 (0.2–0.9)               | 0.6     |
| CA 19.9, kU/L                      | 16.5 (7–50)             | 201 (33–1646)               | <0.01   |

Results are presented as medians (IQR); Wilcoxon-Mann-Whitney test.

Abbreviations

AIP, auto-immune pancreatitis; AUC, area under the curve; CA 19.9, carbohydrate antigen 19.9; HPF, high power field; IgG4-RD, IgG4-related disease; IRC, IgG4-related cholangitis; PSC, primary sclerosing cholangitis; ROC, receiver operating characteristics.

Financial support

Funding provided by the Dutch Digestive Foundation (MLDS) to UB.

Conflict of interest

The authors declare no conflicts of interest that pertain to this work.

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors’ contributions

Based on CRedit. EV – Data curation, Formal analysis, Investigation, Project administration, Writing (original draft); FT – Data curation, Formal analysis, Investigation, Project administration, Writing (original draft); LH – Conceptualization, Funding acquisition, Writing (review & editing); JH – Data curation, Project administration, Software; NM – Software, Validation, Visualization, Writing (review & editing); JV – Investigation, Writing (review & editing); jVHo – Project administration, Resources, Writing (review & editing); MB – Writing (review & editing); PF – Resources, Writing (review & editing); NV – Conceptualization, Methodology, Supervision, Writing (review & editing); UB – Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing (original draft), Writing (review & editing).

Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhepr.2020.100116.

References

Author names in bold designate shared co-first authorship

[1] Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet 2015;385:1460–1471.
[2] Hubers LM, Maillette de Buy Wenniger LJ, Doorenspleet ME, Klarenbeek PL, Verheij J, Rauws EA, et al. IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol 2015;48:198–206.
[3] Ghazale A, Charl ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008;134:706–715.
[4] Tokala A, Khalili K, Menezes R, Hirschfeld G, Jhaferi KS. Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. AJR Am J Roentgenol 2014;202:536–543.
[5] Vlachou PA, Khalili K, Jang HJ, Fischer S, Hirschfeld GM, Kim TK. IgG4-related sclerosing disease: autoimmune pancreatitis and extrahepatic manifestations. Radiographics 2011;31:1379–1402.
[6] Kloek JJ, van Delden OM, Erdogan D, ten Kate FJ, Rauws EA, Busch OR, et al. Differentiation of malignant and benign proximal bile duct strictures: the diagnostic dilemma. World J Gastroenterol 2008;14:5032–5038.
[7] Gerritsen A, Molenaar IJQ, Bollen TL, Nio CY, Dijkstra MG, van Santvoort HC, et al. Preoperative characteristics of patients with presumed pancreatic cancer but ultimately benign disease: a multicenter series of 344 pancreatoduodenectomies. Ann Surg Oncol 2014;21:3999–4006.
[8] Roos E, Hubers LM, Coelen RJS, Doorenspleet ME, de Vries N, Verheij J, et al. IgG4-Associated cholangitis in patients resected for presumed perihilar cholangiocarcinoma: a 30-year tertiary care experience. Am J Gastroenterol 2018;113:765–772.
[9] Erdogan D, Kloek JJ, ten Kate FJ, Rauws EA, Busch OR, Gouma DJ, et al. Immunoglobulin G4-related sclerosing cholangitis in patients resected for presumed malignant bile duct strictures. Br J Surg 2008;95:727–734.

Short communication

JHEP Reports 2020 vol. 2 | 100116
[10] Oseini AM, Chaiteerakij R, Shire AM, Ghazale A, Kaiya J, Moser CD, et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology 2011;54:940–948.

[11] Boonstra K, Culver EL, de Buy Wenniger LM, van Heerde MJ, van Erpecum KJ, Poen AC, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology 2014;59:1954–1963.

[12] Doorenspleet ME, Hubers LM, Culver EL, Maillette de Buy Wenniger LJ, Klarenbeek PL, Chapman RW, et al. Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. Hepatology 2016;64:501–507.

[13] Kamisawa T, Takuma K, Tabata T, Inaba Y, Egawa N, Tsuruta K, et al. Serum IgG4-negative autoimmune pancreatitis. J Gastroenterol 2011;46:108–116.

[14] Lin MS, Huang JX, Yu H. Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker. Int J Clin Exp Med 2014;7:744–750.

[15] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237–267.

[16] Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012;25:1181–1192.